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Abstract
Background: During the 2009 H1N1 pandemic, the global health community sought to make vaccine available ‘‘in
developing nations in the same timeframe as developed nations.’’ However, richer nations placed advance orders with
manufacturers, leaving poorer nations dependent on the quantity and timing of vaccine donations by manufacturers and
rich nations. Knowledge of public support for timely donations could be important to policy makers during the next
pandemic. We explored what the United States (US) public believes about vaccine donation by its country to poorer
countries.
Methods and Findings: We surveyed 2079 US adults between January 22nd and February 1st 2010 about their beliefs
regarding vaccine donation to poorer countries. Income (p = 0.014), objective priority status (p = 0.005), nativity, party
affiliation, and political ideology (p,0.001) were significantly related to views on the amount of vaccine to be donated.
Though party affiliation and political ideology were related to willingness to donate vaccine (p,0.001), there was bipartisan
support for timely donations of 10% of the US vaccine supply so that those ‘‘at risk in poorer countries can get the vaccine at
the same time’’ as those at risk in the US.
Conclusions: We suggest that the US and other developed nations would do well to bolster support with education and
public discussion on this issue prior to an emerging pandemic when emotional reactions could potentially influence
support for donation. We conclude that given our evidence for bipartisan support for timely donations, it may be necessary
to design multiple arguments, from utilitarian to moral, to strengthen public and policy makers’ support for donations.
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Introduction
The first few cases of 2009 H1N1 influenza were detected in
Mexico and California in April 2009. Subsequently, the virus
rapidly spread around the world and a pandemic was declared by
the World Health Organization (WHO) on 11th June 2009 [1].
With the advent of the pandemic, significant attention turned to
the timely production of vaccine to prevent morbidity and
mortality and the first vaccines became available in the United
States (US) in October 2009 [2]. Attention also turned to ensuring
equity in the global distribution of vaccine to countries unable to
afford or finance vaccines themselves. Specifically, the WHO
director-general called for ‘‘international solidarity to provide fair
and equitable access to pandemic influenza vaccines for all
countries’’ [1,3]. The Bill & Melinda Gates Foundation proposed a
set of ethical principles to ‘‘guide the global allocation of pandemic
vaccines,’’ including ‘‘availability of vaccine in developing nations
in the same timeframe as developed nations’’ [4]. In practice,
equitable access to vaccine would mean that countries concur-
rently (or in the same timeframe) receive a proportionate share of
vaccines based on the percentage of their population at risk of
disease, and irrespective of their ability to place advance orders
with vaccine manufacturers, or indeed, their ability to pay. In
other words, equitable global access to vaccines in a pandemic is
dependent on not only the number of doses accessible, but also the
timing of access to vaccines.
Based on these principles, early access to vaccines during the
2009 pandemic, which was largely dependent on nation states’
ability to pay for advance purchase agreements, was inequitable.
Many nations bought vaccine to cover a large proportion of their
population. For example, Canada ordered 50 million doses for 33
million citizens and estimated that 45% of its population was
immunized by January 2010 [5] (See Figure 1 for a timeline of
vaccine availability and donations during the 2009 H1N1
pandemic). Though research in Canada showed that public
support for increased global assistance—even at the expense of
resources for Canadians—existed before the pandemic [6], it was
only one day after the 2nd wave of the flu pandemic was declared
‘‘over’’ in Canada that the country announced that it would
donate five million excess vaccine doses to the WHO [7]. The US
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ordered ,195 million doses at first, adding another 55 million to
make a total of 250 million doses for a population of 300 million
[8]. The country announced on September 17th 2009 that it would
donate 10% of its supply to poorer countries through the WHO
[9]. However, when only limited vaccine became available in
October 2009, vaccine was recommended for target groups in the
US totaling about 160 million people [2] and vaccine donation
was delayed until at-risk people in the US got the vaccine [10,11].
By January 11th 2010, vaccine shortages had eased considerably—
61 million people in the US had received the vaccine—and US
Secretary of Health and Human Services, Kathleen Sebelius,
announced that 25 million doses were ready to ship to the WHO
[12]. Only an estimated five million people accepted the vaccine in
France, which bought 94 million doses; the country tried to sell
excess vaccine to countries with no vaccine in January [13]. The
irony associated with reduced uptake in developed countries of a
vaccine that was completely unavailable to most of the world
population has been commented on by others [14]. Manufacturers
of the vaccine also donated doses. For example, GSK’s vaccine
was approved in September 2009 and the company pledged 50
million doses to the WHO in November 2009. It shipped these
doses beginning in January 2010, approximately three months
after vaccine was first shipped to paying customers [15].
Donations by manufacturers and nations to poorer countries
were coordinated through the WHO. The WHO aimed to
provide vaccine to 95 low- and middle-income countries, home to
two billion people [16], to cover 10% of their population [3]. Two
hundred million doses of vaccine were pledged to the WHO,
including 120 million doses from US, Australia, Brazil, France,
Italy, New Zealand, Norway, Switzerland, and Britain [17]. The
first shipments of donated vaccine to arrive in a developing nation
reached Mongolia in January 2010 [18] compared to the arrival
and availability of vaccine in the US and France, for example, in
October 2009 [2,19]. As of August 2nd 2010 (close to the official
end of the pandemic), 65 countries had received 60.5 million
donated vaccine doses [18].
In sum, sufficient vaccine was donated to cover 10% of the
population of poor countries whereas much larger proportions of
countries receiving the earliest doses were covered; the principle of
equitable access, as defined by the Gates Foundation, was further
violated because the timing of donations was much after those at
risk in the donating nations had access to vaccine (See Figure 1 for
a timeline of the pandemic).
Given a similar risk for specific populations across select
nations—based on the hemisphere, season, number of detected
cases, and demographic features of the population—we contend
that it becomes a moral issue or an issue of justice for access to be
dependent on a nation’s ability to pay for doses through advance
purchase agreements [20]. The nature of the 2009 H1N1
pandemic resulted in surplus doses in many countries easing the
decision to donate purchased vaccine doses [21] and reduced
demand from poorer nations; however, in the event of a more
severe pandemic with higher mortality rates, demand could
outstrip supply of vaccines, leaving nations unwilling to donate
vaccine at all.
Facilitated by the WHO, the ‘‘Open-Ended Working Group of
Member States’’ negotiated a ‘‘Pandemic Influenza Preparedness
Framework for the Sharing of Influenza Viruses and Access to
Vaccines and Other Benefits’’ [22,23,24]. The framework,
presented to the World Health Assembly in 2011, authorizes the
WHO to establish and maintain a stockpile of 150 million doses of
H5N1 vaccine, of which 100 million doses are meant for
distribution to developing countries in need once a pandemic
begins [24]. Such a stockpile would enable timely access to vaccine
in developing countries in the event of an H5N1 pandemic,
though the adequacy of the size of the stockpile will depend on the
severity of the pandemic. The framework also encourages WHO
member states to ‘‘consider making donations and in-kind
contributions’’ to the WHO to improve global pandemic
preparedness. Efforts to build self-sufficiency in developing
nations’ vaccine production capabilities have been limited in the
past and focused on diseases other than influenza [25]. The US
recently announced grants to the WHO to strengthen developing
countries’ ability to produce flu vaccine [26], but voluntary
donations by rich countries are likely to remain an important
means of access to vaccines across the globe in an influenza
Figure 1. Timeline of the 2009 H1N1 Pandemic.
doi:10.1371/journal.pone.0033025.g001
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pandemic in the foreseeable future in spite of the Pandemic
Influenza Preparedness Framework [24], especially in the event of
a severe pandemic, or a non-H5N1 pandemic.
Accurate knowledge of the potential public support for such a
decision could be important to policy makers. We explored what
the US public believes about vaccine donation by their country to
poorer countries. We hypothesize that views on this issue will vary
by demographic characteristics, at-risk status, party affiliation and
political ideology, as well as whether the respondent has access to
healthcare resources. We describe our findings and provide broad
recommendations for researchers, advocacy groups, policy mak-
ers, and the public. We contend that on the one hand,
governments of developed nations may be able to call on
principles of fairness and equity to donate vaccine to poorer
nations in a timely manner, and on the other, public and advocacy
groups could, in turn, call upon those principles in advocating to
policy makers for decisions to donate vaccine such that nations
would have concurrent access to vaccines in a pandemic.
Methods
This study was approved by the University of Pittsburgh
Institutional Review Board. Knowledge Network provided an
anonymized data file for analysis and all data were analyzed
anonymously.
A representative sample of the US population was randomly
drawn from the Knowledge Networks (KN) online research panel.
To recruit people to the panel, KN uses random-digit dial and
address-based probability sampling methods and provides panelists
with access to the internet and hardware, if necessary. For this study,
a national sample of 3689 adults aged $18, including oversamples
of African American and Hispanics, was contacted by email.
Between January 22nd and February 1st 2010, 2079 respondents
completed the survey for a 56% completion rate. KN provided a
data file with weighting variables, which incorporate design-based
weights to account for the recruitment of panelists and both panel-
based and study-specific post-stratification weights benchmarked
against the most recent Current Population Survey (CPS) with
respect to demographic and geographic distributions of the
population aged $18. Information on the KN panel is available
from their website [27],[28].
Survey Instrument and Measures
The questionnaire focused on attitudes towards the 2009 H1N1
virus (identified interchangeably as swine flu) and donation of the
H1N1 influenza vaccine. KN collects demographic variables as
part of its research procedures.
To gauge access to healthcare resources in general, we asked if
the respondent has health insurance. We assessed perceived access
to the vaccine using our measure of subjective presence in a
priority group for the vaccine. We measured ‘‘Subjective Priority’’
using the item, ‘‘Are you in a priority group to get the swine flu
vaccine first?’’ (‘‘No’’ and ‘‘Don’t know’’ collapsed into ‘‘No’’). At-
risk status was assessed using ‘‘Objective Priority,’’ which was
computed as a dichotomous variable based on the ACIP’s
recommendations [29]. We asked if respondents had been told
by a health professional that they had any of 9 chronic medical
conditions. We gave those aged 25–64 years with a chronic
condition, pregnant women, respondents aged 18–24, and those
who reported being caretakers of children aged ,6 months or
healthcare/emergency medical services personnel a score of 1; all
others got a score of 0 (‘No’).
We asked two questions about influenza vaccine donation: ‘‘The
US government is donating 10% of the 195 million doses of
vaccine it has purchased to the World Health Organization
(WHO) to distribute in poor countries that do not have the
resources to buy their own vaccine.’’ We first asked how the
respondent viewed willingness to donate the amount of vaccine
being donated: ‘‘a. The US should not donate vaccine it has
purchased; b. The US should donate less than 10% of its
purchased vaccine; c. The US should donate more than 10% of its
purchased amount of vaccine; d. A donation of 10% of its
purchased vaccine by the US is just right.’’ Next, we asked how the
respondent felt about the timing of the donation: ‘‘a. The US
should donate vaccine after everyone who wants it here has gotten
the vaccine; b. The US should donate vaccine after those at high-
risk here have gotten the vaccine; c. The US should donate
vaccine now so that people at risk in poor countries can get the
vaccine at the same time as those at risk here.’’
Results
The demographic characteristics of the entire sample, including
access to health insurance as well as subjective and objective
priority, are shown in Table 1.
Views on the amount of vaccine donated
As shown in Table 2, 55.7% of respondents felt that a donation
of 10% of purchased vaccine by the US to poorer countries was
‘‘just right.’’ Greater than 21% felt the US should donate more
than 10% of its vaccine, in contrast to only 16% who felt that the
country should not donate vaccine at all, and 6.8% who felt that a
donation of less than 10% would be appropriate.
Income (p = 0.014), objective priority status (p = 0.005), nativity,
party affiliation, and political ideology (p,0.001) were significantly
related to views on the amount of vaccine to be donated (Table 2).
Close to 28% of people in the lowest income category believed that
the US should donate greater than 10% of purchased vaccine
compared to close to 20% of those in higher income categories.
Whereas subjective priority was not significantly related to views
on vaccine donation, 26.4% of those objectively in a priority group
to receive vaccine compared to 16.5% of those not in a priority
group to receive vaccine felt that the US should donate more than
10% of its purchased vaccine. Nativity (born in the US or not) was
significantly related to views on the amount of vaccine donation
(p,0.001). These results suggest that immigrants, poorer people,
and those at greater risk in the US were more willing to share
vaccine than others were.
We found that party affiliation and political ideology were
related to vaccine donation (p,0.001). According to our study,
greater than 26% of Democrats felt that the country should
donate greater than 10% of its purchased vaccine compared to
14.3% of Republicans. Yet, greater than 50% of each believed
that a donation of 10% of vaccine by the US was ‘‘just right.’’
Similarly, 28.8% of liberals but only 12.7% of conservatives
believed that the US should donate more than 10% of its
vaccine; a majority of conservatives, moderates, and liberals,
however, believed that a donation of 10% was ‘‘just right’’
(Table 2). We obtained similar results in a multinomial logistic
regression model examining views on the amount of vaccine
donated as the outcome and the characteristics shown in Table 2
as independent variables though ideology was no longer related
to the outcome after controlling for party affiliation (results
available on request).
Views on the timing of donations
All respondents other than those who felt that the US should not
donate any vaccine were asked if vaccine should be donated after
Pandemic Vaccine Donation
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those in the US had received it or at a time such that those at risk
in other countries could get it concurrently with those at risk in the
US. 44.9% felt that vaccine should be donated ‘‘now so that
people at risk in poor countries can get the vaccine at the same
time as those at risk here’’ compared to 31.3% who felt that
donations should be made after those at risk here got the vaccine
and 23.8% who felt that donations should happen only after those
who want the vaccine in the US had received it (Table 3).
Education (p = 0.030) and nativity (p = 0.001) were related to
views on the timing of donations. Greater than 58% of those with
the lowest level of education but less than 45% of those with higher
levels of education felt that donations should occur so that those at
risk in poorer countries have access to the vaccine at the same time
as those at risk here. Of those born outside the US, 58.1%,
whereas 42.1% of those born in the US believed that donations
should enable access to those at risk in poorer countries at the
same time as those at risk in the US. Somewhat surprisingly, other
demographic and party affiliation/ideological characteristics were
not significantly related to views on the timing of vaccine donations.
Though education remained significantly related to views on the
timing of donations in a multinomial logistic regression model with
all characteristics in Table 3 as independent variables, nativity was
no longer significantly related to the outcome (results available on
request).
Support for prioritization in determining who gets
limited supplies of vaccine in the US
Donating larger amounts of purchased vaccine or donating
vaccine early such that those at risk elsewhere have access
concurrently with those at risk in the US would necessitate
prioritization in the US to determine who gets limited supplies of
vaccine. We examined support for such prioritization. As shown in
Table 4, bipartisan support for such prioritization in the US exists
(p = 0.394 for a difference between Republicans and Democrats),
providing evidence that larger and earlier donations leading to
limited availability and prioritization of vaccine in the US may be
politically possible.
Discussion
Ensuring timely access to influenza vaccine throughout the
world is a public health goal of the WHO. We have shown that
there exists considerable support for timely donations of at least
10% of the US share of vaccines during a pandemic. We
acknowledge, however, that our study was conducted in the
context of a pandemic in which illness was mild for most and the
overall fatality rate was lower than the severe 1918 Spanish
influenza pandemic with which it was often compared in media
characterizations of the pandemic. The perception that the disease
was mild may have played a role in recipients’ support for timely
vaccine donations. Our results encourage further research—
including experimental studies employing hypothetical scenarios
such as pandemics caused by a virulent viral strain—to understand
the public’s potential attitudes toward vaccine donations in a
severe pandemic.
Vaccine donations are a political and fiscal decision within
donor countries. Developing political consensus for timely
donation of influenza vaccines during a pandemic is a challenge.
For example, though research showed that public support for
increased global assistance during a pandemic existed in Canada
[6], the absence of public and political discourse regarding this
issue presumably made it impossible for the government to donate
excess doses until after the 2nd wave of the flu pandemic was
declared ‘‘over’’ [7]. It may also be challenging to garner the fiscal
resources to support vaccine availability internally as well as to
ensure adequate supply for donation to other countries. Therefore,
to address these policy decisions requires discussion and planning
before as opposed to during the next pandemic. This may be
Table 1. Demographics of the overall sample.
Overall
Characteristic Na %b
Total 2079 100
Income
Under 25 K 550 25.0
25 K–49 K 582 25.1
50 K–75 K 401 22.3
$75 K 546 27.6
Education
,High School 311 13.8
High School 674 30.8
Some College 591 28.1
$Bachelor’s degree 503 27.2
Gender
Male 975 48.8
Female 1089 51.2
Age, years
Mean (SE) 46.6 (0.70)
Race/Ethnicity
White, NHc 849 69.3
Black, NHc 591 11.6
Hispanic 602 14.2
Other, NHc 37 4.8
Health Insurance
No 480 21.9
Yes 1565 78.1
Subjective Priority
No 1661 81.9
Yes 399 18.1
Objective Priority
No 1002 48.9
Yes 1077 51.1
Born in US
No 398 11.9
Yes 1634 88.1
Party
Republican 651 40.8
Independent 71 3.4
Democrat 1353 55.8
Ideology
Liberal 626 29.8
Moderate 753 34.1
Conservative 681 36.1
aUnweighted N;
bWeighted %;
cNon-Hispanic.
doi:10.1371/journal.pone.0033025.t001
Pandemic Vaccine Donation
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33025
increasingly important in the current fiscal environment for many
countries.
Our results suggest that there is more public support for vaccine
donations in the US than policy makers may have expected.
Considerable bi-partisan—though short of majority—support
exists for the timely donation of 10% of vaccine. If global health
advocacy groups wanted to boost support within the US for
vaccine donations to poorer countries, they could potentially
frame either a moral argument that is based on justice or a
utilitarian argument that we live in a global economy, which
makes it critically important for economic reasons that vaccine
must be available throughout the world in order to maintain the
‘just-in-time’ distribution of products and goods across the globe.
Arguments can also be centered on maintaining basic capabilities
and functionings of people in poorer countries [30]: in countries
that lack adequate access to high quality curative healthcare,
increased access to vaccines (at a level depending on people’s
vulnerability) could be imperative if people are to maintain their
livelihood and other capabilities during a pandemic. Arguments
could be received differently, however, depending on the political
ideology of the recipient. Recent multi-stage research conducted
recently—employing qualitative focus groups and quantitative
survey methods—furthered understanding of not only how the
public and opinion elites understand messages dealing with
another public health issue with moral underpinnings—health
disparities and the social determinants of health—but also of
wording of messages that would most resonate with the public and
build support for evidence-based policy change [31]. We suggest
the need for similar research on message wording that would
resonate in a bi-partisan manner to build further support for
vaccine donations in future pandemics.
We found support for donation among lowest income groups
who were, in fact, the most likely to support donation of more than
10%. That nativity was related to views on the amount and timing
of vaccine donations is a potentially interesting finding. In the
absence, however, of knowledge regarding the country of origin
for those not born in the US, we hesitate to draw a generalizable
conclusion from this finding.
Although we found substantial support for donation, the 2009
H1N1 pandemic was perceived by many to be mild and it is
unclear what the impact on attitudes would be if mortality rates
were higher in a pandemic. Future research should explore the
extent to which severity may affect public attitudes and political
calculations of policy makers. While one might speculate that
severity may decrease public willingness to support donation, an
economic and pragmatic argument, which focuses on the critical
importance of vaccine worldwide to maintain the global just in
time economy, may yet be persuasive. Policy makers may also
imagine that in a more severe pandemic, support for donation
would decrease if it requires prioritization of vaccine distribution
in the US. However, we did find bipartisan support for
prioritization of vaccine recipients; prioritization would, in reality,
have to occur, at least initially in a pandemic, regardless of vaccine
donation decisions.
Table 2. Characteristics of respondents to question regarding the scale of vaccine donation.
N (%){
US is donating 10% of its purchased vaccine;
How do you feel about the amount?*
Should not
donate vaccine
Should donate
,10%
Should donate
.10%
A donation of
10% is just right p-value
Total (N=1999) 237 (16.0) 122 (6.8) 539 (21.5) 1101 (55.7)
Income ,$25 K 36 (8.2) 33 (6.9) 170 (27.9) 279 (57.0) 0.014
$25–49 K 63 (20.9) 25 (4.0) 164 (19.3) 314 (55.8)
$50–74 K 60 (18.2) 27 (8.6) 89 (20.5) 212 (52.7)
$$75 K 78 (16.6) 37 (7.8) 116 (18.7) 296 (57.0)
Education ,High School 22 (12.0) 20 (7.0) 94 (22.3) 154 (58.7) 0.275
High School 68 (16.0) 37 (8.3) 185 (21.2) 354 (54.4)
Some College 86 (22.9) 34 (6.5) 135 (21.2) 319 (49.4)
$Bachelor’s Degree 61 (10.7) 31 (5.3) 125 (21.8) 274 (62.2)
Health Insurance No 44 (12.6) 26 (5.2) 154 (23.0) 243 (59.2) 0.352
Yes 189 (16.8) 96 (7.3) 379 (21.0) 855 (54.8)
Subjective Priority No 193 (17.0) 100 (6.3) 427 (21.0) 878 (55.7) 0.297
Yes 43 (11.7) 22 (9.1) 109 (23.8) 221 (55.4)
Objective Priority No 115 (17.4) 62 (8.6) 227 (16.5) 559 (57.4) 0.005
Yes 122 (14.6) 60 (5.1) 312 (26.4) 542 (54.0)
Born in US No 21 (8.8) 15 (5.9) 157 (36.9) 191 (48.3) ,0.001
Yes 209 (16.7) 106 (7.2) 371 (19.4) 892 (56.8)
Party Republican 130 (22.0) 47 (6.0) 97 (14.3) 354 (57.6) ,0.001
Democrat 103 (11.4) 74 (7.7) 420 (26.8) 715 (54.1)
Ideology Liberal 47 (12.1) 34 (6.6) 209 (28.8) 314 (52.4) ,0.001
Moderate 81 (15.4) 35 (5.7) 199 (24.4) 412 (54.5)
Conservative 109 (19.9) 52 (7.9) 127 (12.7) 369 (59.5)
{Unweighted N, Weighted %;
*See Methods for exact wording.
doi:10.1371/journal.pone.0033025.t002
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Ensuring that influenza vaccine is available in adequate supplies
and distributed in a timely manner during an influenza pandemic
is a global public health goal. As part of the ‘Open-Ended
Working Group of Member States’ of the WHO [22], countries
negotiated a potential material transfer agreement that will govern
the transfer and use of biological materials and resulting products
during a pandemic. Neither the agreement nor our study addresses
the issue of delays in vaccine delivery after receipt of donated
shipments by the WHO or the ethical implications of requiring
poorer nations to meet stringent conditions before receiving
donation shipments; these are subjects for future research.
The new ‘Open-Ended Working Group of Member States’
framework [24] stipulates that a recipient (such as a vaccine
manufacturer) of viral material commit to donating ‘‘at least 10%
of real-time pandemic vaccine production to the WHO,’’ and
reserve an equal amount ‘‘at affordable prices to WHO.’’ Faced
with a severe pandemic, however, demand for scarce vaccine in
poorer nations could outstrip the 20% of production available to
the WHO under this framework. In such a scenario, it may
become morally imperative for countries with large advance
purchase agreements with vaccine manufacturers to consider
donating vaccine to poorer countries. We argue that in light of our
results, it is important for US policy makers as well as international
partners to have a clear understanding of existing public support
for timely vaccine donations. In order to frame arguments that
would resonate in a bi-partisan manner, further research on
Table 3. Characteristics of respondents to question regarding the timing of vaccine donation.
N (%){
US is donating 10% of its purchased vaccine;
How do you feel about the timing?*
Donate after those
who want get it*
Donate after at-risk
get it*
Donate now so that at-risk
everywhere have access* p-value
Total (N=1731) 395 (23.8) 455 (31.3) 881 (44.9)
Income ,$25 K 98 (23.5) 98 (26.7) 274 (49.7) 0.129
$25–49 K 124 (27.4) 120 (26.6) 255 (46.0)
$50–74 K 69 (17.2) 98 (37.1) 158 (45.7)
$$75 K 104 (26.4) 139 (35.1) 194 (38.5)
Education ,High School 50 (17.3) 58 (24.5) 153 (58.2) 0.030
High School 140 (31.4) 124 (26.4) 303 (42.3)
Some College 111 (19.2) 150 (40.0) 219 (40.8)
$Bachelor’s Degree 94 (23.1) 123 (32.0) 206 (44.9)
Health Insurance No 95 (23.2) 98 (24.9) 223 (51.9) 0.166
Yes 300 (24.1) 356 (33.3) 651 (42.6)
Subjective Priority No 315 (23.0) 369 (32.0) 697 (45.0) 0.675
Yes 79 (27.3) 86 (28.9) 180 (43.8)
Objective Priority No 186 (20.9) 215 (31.3) 437 (47.8) 0.236
Yes 209 (26.6) 240 (31.3) 444 (42.1)
Born in US No 58 (17.4) 64 (24.5) 234 (58.1) 0.001
Yes 329 (24.7) 385 (33.2) 631 (42.1)
Party Republican 146 (28.1) 134 (32.5) 212 (39.4) 0.100
Democrat 239 (20.9) 311 (30.8) 637 (48.3)
Ideology Liberal 104 (19.0) 150 (28.3) 290 (52.7) 0.090
Moderate 145 (22.1) 171 (35.8) 316 (42.1)
Conservative 143 (29.8) 133 (29.6) 268 (40.6)
{Unweighted N, Weighted %;
*See Methods for exact wording.
doi:10.1371/journal.pone.0033025.t003
Table 4. Bipartisan support for prioritization in determining who gets limited supplies of vaccines or drugs.
Setting priorities on limited supplies of vaccine N (%)* p-value
Strongly Oppose Oppose Favor Strongly Favor
Total 219 (10.3) 551 (24.9) 1019 (55.5) 214 (9.3)
Party Republican 74 (11.9) 168 (23.3) 326 (54.4) 64 (10.4) 0.394
Democrat 136 (8.4) 365 (25.7) 667 (57.3) 144 (8.6)
*Unweighted N, Weighted %.
doi:10.1371/journal.pone.0033025.t004
Pandemic Vaccine Donation
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33025
communication strategies is required. The results of such research
could inform methods to bolster existing support among the public
and to advocate with policy makers on this issue prior to the next
pandemic.
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